Til

Notarc Acquires the Panama Canal Container Port Terminal and Will Resume Construction of the $1.4 Billion Project

Retrieved on: 
Thursday, May 19, 2022
PANAMA, SPV, TIL, World, SGP, Investment, Goal, Transport, PCCP, FDI, Mediterranean Shipping Company, MSC, Industry, Til, Partnership, Republic, Conference, Technology, Panama Canal, Acquisition, GLOBE, PDF, CEO, NMG, Intermodal freight transport, Renewable energy

The project is already forty percent (40%) completed and is slated to resume construction by the fourth quarter of 2022.

Key Points: 
  • The project is already forty percent (40%) completed and is slated to resume construction by the fourth quarter of 2022.
  • "We are delighted to be here for this special occasion and to commit to the partnership with Notarc, the Panamanian Government and, most importantly, the people of Panama.
  • "SGP is excited to join Notarc in the development of these transformational projects for Panama and the region.
  • Notarc Management Group comprises leading investment and asset management professionals in UK, Europe, Panama, Asia, The Bahamas, and The United States.

MSC Group and Mercy Ships Celebrate 10 Years of Partnership

Retrieved on: 
Monday, December 13, 2021
Surgery, General Health, Infectious Diseases, Foundation, Philanthropy, Hospitals, Dental, Consumer, Other Transport, Health, Maritime, Other Philanthropy, Transport, Training, Logistics, Supply Chain Management, Education, Women, Revolution, Mediterranean Shipping Company, Global, African, Mercy Ships, COVID, Hope, MSC, Capacity building, Environment, Company, SNAV, Awareness, Volunteering, PPE, Group, MSC Cruises, Time, GNV, Dentist, Nursing, Community Support Group, Transport, Til, MV Empire MacAndrew, Surgeon, Program, Multimedia, Education, Housekeeping, MV Global Mercy, Port, Grandi Navi Veloci, Partnership, Foundation, Medicine, Civil engineering, Animal, Tourism

This month MSC Group and Mercy Ships are celebrating a unique ten-year partnership focused on bringing hope and healing in Africa.

Key Points: 
  • This month MSC Group and Mercy Ships are celebrating a unique ten-year partnership focused on bringing hope and healing in Africa.
  • Mercy Ships partnership with the MSC Group and MSC Foundation helps meet these and wider needs, with the MSC Groups cargo business having grown to become a world leader in container shipping and logistics, while MSC Cruises is now the third-largest cruise brand in the world.
  • MSC Cruises stepped in very soon afterwards, providing maritime best practice and ship management expertise to support the Mercy Ships crew.
  • MSC Group provided logistical support and the container delivery of supplies needed to build the Global Mercy.

Drake Partners with The Ultimate Rap League and Caffeine to Throw a Battle Rap Event for His Birthday Called 'Til Death Do Us Part'

Retrieved on: 
Monday, October 25, 2021
Universe, Samsung Electronics, Apple TV, Mitchell, NBA, MLB, GRAMMY, Roku, UFC, Ultimate Rap League, Amazon Fire TV, PDT, Twitter, Partnership, NFL, Til, CEO, Movement, EDT, XBOX, Android, Culture, URL, Mobile phone

The mega-event will be hosted by Drake to celebrate his birthday and URL's 12th Anniversary on Saturday, October 30, 2021.

Key Points: 
  • The mega-event will be hosted by Drake to celebrate his birthday and URL's 12th Anniversary on Saturday, October 30, 2021.
  • With battles hand selected by the Hip-Hop icon, Drake's Til Death Do Us Part will tap the most elite emcees from multiple generations of battle rap to go head-to-head.
  • "Drake's Til Death Do Us Part is not just a birthday celebration for our friend," Smack shares.
  • In 2020, Drake inked an exclusive deal between the Ultimate Rap League and Caffeine.

Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates

Retrieved on: 
Thursday, August 5, 2021
IOV, Health, Patent, IL-2, Method, PD-L1, Manuscript, Cryopreservation, Cervical cancer, Cancer, Non-small-cell lung carcinoma, SAN, Pembrolizumab, Poster, Safety, American Society of Clinical Oncology, Annual general meeting, Transcription activator-like effector nuclease, Asco, PBL, Metastasis, Melanoma, Annual report, Private Securities Litigation Reform Act, Food and Drug Administration, Research, Interim, Security (finance), Risk, Investor, Orr, Population, Technology, Growth, Perception, Til, Food, Nasdaq, GLOBE, U.S. Securities and Exchange Commission, Investment, American Journal of Clinical Oncology, Programmed cell death protein 1, Journal, Lymphatic system, Dor, Patient, COVID-19, Society, BLA, Information, Forward-looking statement, Pharmaceutical industry, Medical imaging, Animal

SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.

Key Points: 
  • SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.
  • Research and development expenses were$62.1 millionfor the second quarter endedJune 30, 2021, an increase of$12.8 millioncompared to$49.3 millionfor the second quarter endedJune 30, 2020.
  • General and administrative expenses were$19.3 millionfor the second quarter endedJune 30, 2021, an increase of$5.0 millioncompared to$14.4 millionfor the second quarter endedJune 30, 2020.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the second quarter 2021 financial results and corporate updates.

Orgenesis Second Quarter 2021 Revenue Increases Over Six-Fold to $10.5 Million Compared to Second Quarter 2020 Reflecting Continued Progress of POCare Platform

Retrieved on: 
Thursday, August 5, 2021
Company, Hospital for Special Surgery, University of California, Davis, Chief executive officer, Research, UC, U.S. Securities and Exchange Commission, Industry, Hospital, Tissue, Telephone, Coronavirus, Technology, Annual report, Security (finance), Risk, Partnership, Contract, Securities Act of 1933, SVF, Patient, Foundation, ICELL Network, Johns Hopkins University, Technology transfer, An Act to exempt a particular class of securities from the Securities and Exchange Act, JV, Energy Independence and Security Act of 2007, Til, CGT, Work, Ranpirnase, Protest and strikes of the CGT union 2021, Diabetes, Therapy, Environment, Acquisition, Nasdaq, Traction, GLOBE, Pharmaceutical industry, Online shopping

Vered Caplan, CEO of Orgenesis, stated, I am pleased to report that our POCare revenues for the second quarter of 2021 increased more than six-fold to $10.5 million compared to $1.75 million for the second quarter of last year, which reflects the sustainability of our POCare strategy.

Key Points: 
  • Vered Caplan, CEO of Orgenesis, stated, I am pleased to report that our POCare revenues for the second quarter of 2021 increased more than six-fold to $10.5 million compared to $1.75 million for the second quarter of last year, which reflects the sustainability of our POCare strategy.
  • As an example, we recently entered into an agreement with a local partner to expand our POCare network in Australia.
  • At the same time, we are incorporating into our clinical activity a number of highly advanced, automated POCare technologies.
  • Our goal is to validate our POCare platform, while building the foundations for our market expansion in the various geographic regions.

Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Health, Life sciences, Instil, Tumor-infiltrating lymphocytes, Melanoma, Orphan drug, Til

b'Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168\nDALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (\xe2\x80\x9cInstil\xe2\x80\x9d) (NASDAQ: TIL), a clinical-stage biopharmaceutical company developing tumor infiltrating lymphocytes, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2021 financial results and provided a corporate update.\n\xe2\x80\x9cIn March of 2021, Instil completed an initial public offering to support the development of our TIL therapies.

Key Points: 
  • b'Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168\nDALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (\xe2\x80\x9cInstil\xe2\x80\x9d) (NASDAQ: TIL), a clinical-stage biopharmaceutical company developing tumor infiltrating lymphocytes, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2021 financial results and provided a corporate update.\n\xe2\x80\x9cIn March of 2021, Instil completed an initial public offering to support the development of our TIL therapies.
  • \xe2\x80\x9cWe recently presented clinical data from our compassionate use program at the AACR conference and received orphan drug designation from the U.S. Food and Drug Administration for ITIL-168 in melanoma.
  • The gross proceeds of the offering were $368 million, before underwriting discounts and commissions and other offering expenses payable by Instil.
  • Instil also expects U.S. clinical manufacturing to be online in the first half of 2022.\nAs of March 31, 2021, cash and cash equivalents totaled $609.6 million, compared to $241.7 million as of December 31, 2020.

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates

Retrieved on: 
Thursday, November 5, 2020
Iovance Biotherapeutics, Lymphocytes, Tumor-infiltrating lymphocytes, NASDAQ, Til, Companies, Finance, Economy of the United States

SAN CARLOS, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported third quarter 2020 financial results and provided a corporate update.

Key Points: 
  • SAN CARLOS, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported third quarter 2020 financial results and provided a corporate update.
  • Iovance development program: to date, over 400 patients have been dosed with Iovance TIL products with more than 90 percent manufacturing success rate.
  • Research and development expenses were$43.1 millionfor the third quarter endedSeptember 30, 2020, an increase of$1.5 millioncompared to$41.6 millionfor the third quarter endedSeptember 30, 2019.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the third quarter and year-to-date 2020 financial results and to provide a corporate update.

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, May 5, 2020
Food and Drug Administration, Iovance Biotherapeutics, Til, AT4, Biologics license application, Companies, Economy of the United States

SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020 financial results and provided a corporate update.

Key Points: 
  • SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020 financial results and provided a corporate update.
  • Iovance continues preparing for submission of a Biologics License Application (BLA) in late 2020 through data compilation as well as internal readiness activities.
  • General and administrative expenses were$13.9 millionfor the first quarter 2020, an increase of$4.8 millioncompared to$9.1 millionfor the first quarter 2019.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the first quarter 2020 financial results and to provide a corporate update.

RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors

Retrieved on: 
Friday, May 11, 2018
Biotechnology companies, RXi Pharmaceuticals, Cancer immunotherapy, Til, Tumor-infiltrating lymphocytes, Medicine, Health

Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, stated: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology.

Key Points: 
  • Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, stated: "Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology.
  • Our agreement will allow Iovance to explore their proprietary TIL technology and our proprietary sd-rxRNA technology.
  • Under this research collaboration, we will further investigate and expand the recently published data with TIL and sd-rxRNA products, which demonstrated potentially enhanced tumor killing activity of TIL."
  • RXi Pharmaceuticals Corporation(NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA) therapeutic platform.